文献速递妇科肿瘤

MFAP5在卵巢癌中的表达及其对癌细胞增殖、转移和耐药的影响

[The expression of MFAP5 in ovarian cancer and its effect on cancer cell proliferation, metastasis and drug resistance].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2025-01-01

该研究通过在线数据库、组织芯片免疫组化及体外实验探讨MFAP5在卵巢癌中的表达及作用。结果显示MFAP5在卵巢癌间质高表达,与不良预后相关,敲降CAFs中MFAP5可减弱对SKOV3细胞迁移、侵袭和耐药的支持,机制与AKT通路相关。

要点

  • MFAP5在卵巢癌间质高表达,晚期高级别表达更高,高表达提示不良预后。
  • 敲降CAFs中MFAP5可减少SKOV3迁移侵袭并增加化疗敏感性。
  • MFAP5通过激活AKT通路支持卵巢癌细胞恶性行为及耐药。

核心结论

  • MFAP5在卵巢癌间质高表达,高表达预示预后较差。
  • 敲降CAFs中MFAP5可减弱对卵巢癌细胞恶性行为及耐药的支持。
  • 该作用机制可能与阻断卵巢癌细胞AKT信号通路有关。

研究设计与样本

  • 研究采用在线数据库分析、组织芯片免疫组化及体外细胞实验。
  • 组织芯片标本来自河南省人民医院2018年1月至2023年3月。
  • 体外实验使用卵巢癌细胞SKOV3与CAFs共培养体系。

主要发现

  • 卵巢癌组织MFAP5表达明显高于正常卵巢组织(P<0.001)。
  • MFAP5表达主要集中于卵巢癌间质,分期越晚、分级越高表达越高。
  • MFAP5高表达与不良预后相关,仅在较晚分期、较高级别中意义明显。
  • ssGSEA显示MFAP5表达与上皮间充质转化、迁移、侵袭基因集评分成正相关(均P<0.001)。
  • 敲降CAFs中MFAP5可增加SKOV3对化疗、维持治疗的敏感性。

关键数值与推荐

  • GSE9891数据集中MFAP5与上皮间充质转化、迁移、侵袭评分的r值分别为0.54、0.40、0.67(均P<0.001)。
  • TCGA594数据集中上述r值分别为0.41、0.29、0.56(均P<0.001)。
  • 细胞迁移数:对照组73.44±7.80个,si-NC组199.74±18.26个,si-MFAP5组91.21±6.70个。
  • 细胞侵袭数:对照组61.62±8.76个,si-NC组174.81±15.23个,si-MFAP5组67.17±9.83个。

临床怎么用

  • MFAP5高表达可作为卵巢癌不良预后的潜在生物标志物。
  • 靶向CAFs中MFAP5或AKT通路可能成为减弱卵巢癌恶性行为及耐药的策略。

局限性

  • 研究以体外实验为主,缺乏体内动物实验验证。
  • 组织芯片标本来源单一,样本量未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the expression of microfibril-associated protein 5 (MFAP5) in ovarian cancer and its influence on malignant behavior of ovarian cancer cells. Methods: GEPIA, CSIOVDB and Kaplan-Meier Plotter online databases were used to analyze the expression of MFAP5 in various tumor tissues, especially in ovarian cancer. Immunohistochemistry was used to detect the expression level of MFAP5 in ovarian cancer tissue chip (The tissue microarray was commissioned to Zhongke Guanghua [Xi'an] Intelligent Biotechnology Co., Ltd. for processing. The specimens were sourced from Henan Provincial People's Hospital from January 2018 to March 2023), and the relationship between MFAP5 expression and the clinical characteristics of patients with ovarian cancer was analyzed using SPSS software. Kaplan-Meier Plotter online database was used to analyze the relationship between MFAP5 expression and survival prognosis of ovarian cancer patients. The ovarian cancer data sets GSE9891 and TCGA594 were downloaded from GEO and TCGA respectively, and ssGSEA was used to analyze the scores of gene sets related to epithelial mesenchymal transition, migration and invasion in ovarian cancer data sets. Next, the relationship between MFAP5 expression and the above scores was analyzed using GraphPad Prism. The expression of MFAP5 in normal fibroblasts (NFs) and cancer associated fibroblasts (CAFs) was verified by western blot. MFAP5 expression in CAFs was reduced by MFAP5-si RNA, and influence of CAFs with high or low expression of MFAP5 on malignant behavior of ovarian cancer cell SKOV3 was verified by transwell test. The influence of CAFs with high or low expression of MFAP5 on epithelial mesenchymal transition markers of ovarian cancer cell SKOV3 was verified by western blot. The CCK8 assay and 3D co-culture model were used to verify the effects of CAFs with high and low MFAP5 expression on the chemoresistance of ovarian cancer cells SKOV3. Transwell assay, western blot, and 3D co-culture model were used to explore and verify the related pathways through which MFAP5 affects the malignant behavior and drug resistance of ovarian cancer cells SKOV3. Results: Online data analysis showed that the expression of MFAP5 in ovarian cancer tissue was significantly higher than that in normal ovarian tissue (P<0.001). Immunohistochemistry showed that the expression of MFAP5 was mainly concentrated in ovarian cancer stroma, and the later stage and the higher grade ovarian cancer tissues showed higher MFAP5 expression. Survival analysis showed that the high expression of MFAP5 was related to the poor prognosis of patients, and it was only significant in later stages and higher grades. ssGSEA analysis showed that the expression of MFAP5 was positively correlated with the scores of gene sets related to epithelial-mesenchymal transition, migration and invasion of ovarian cancer. In vitro experiments showed that reducing the expression of MFAP5 in CAFs could not only partially reduce its supportive effect on the malignant behaviors such as migration and invasion of ovarian cancer epithelial cells SKOV3 (The number of migrating cells in the control group, si-NC group, and si-MFAP5-group was 73.44±7.80, 199.74±18.26, and 91.21±6.70, respectively. The number of invading cells in the control group, si-NC group, and si-MFAP5-group was 61.62±8.76, 174.81±15.23, and 67.17±9.83, respectively), but also increase the sensitivity of ovarian cancer epithelial cells SKOV3 to chemotherapy and maintenance therapy. Further research showed that MFAP5 could activate the AKT signaling pathway in ovarian cancer cells SKOV3, and inhibiting the AKT pathway could block the supportive effect of MFAP5 on the malignant behavior and drug resistance of ovarian cancer cells. Conclusions: MFAP5 is highly expressed in ovarian cancer, especially in the stromal tissue of ovarian cancer, where the expression level is the highest. High expression of MFAP5 often indicates a poor prognosis for ovarian cancer patients. By reducing the expression of MFAP5 in CAFs, the supportive effect on the malignant biological behavior and drug resistance of ovarian cancer epithelial cells can be weakened. The underlying mechanism of this phenomenon may be related to the blockade of the AKT signaling pathway in ovarian cancer cells. 目的: 探讨微纤维相关蛋白5(MFAP5)在卵巢癌中的表达情况及其对卵巢癌细胞恶性行为的影响。 方法: 应用GEPIA、CSIOVDB、Kaplan-Meier Plotter在线数据库分析MFAP5在各种肿瘤组织中的表达尤其是卵巢癌中表达情况,免疫组化检测MFAP5在卵巢癌组织芯片[组织芯片委托中科光华(西安)智能生物科技有限公司加工,标本来源为2018年1月至2023年3月河南省人民医院]中的表达水平并分析其表达与患者临床特点之间的关系,应用Kaplan-Meier Plotter在线数据库分析MFAP5表达与卵巢癌患者生存预后之间的关系。分别从基因表达综合数据库、癌症基因组图谱(TCGA)数据库下载卵巢癌数据集GSE9891、TCGA594,应用ssGSEA分析上皮间充质转化、迁移、侵袭相关基因集在卵巢癌数据集中的评分,并分析MFAP5表达与上述评分之间的关系。Western blot实验验证正常成纤维细胞与肿瘤相关成纤维细胞(CAFs)中MFAP5表达情况,应用MFAP5-siRNA敲降CAFs中MFAP5表达,应用Transwell实验、Western blot实验验证高低表达MFAP5的CAFs对卵巢癌细胞SKOV3恶性行为以及上皮间充质转化标志的影响,细胞计数试剂盒8实验以及3D共培养实验验证高低表达MFAP5的CAFs对卵巢癌细胞SKOV3化疗耐药的影响,Transwell实验、Western blot实验以及3D共培养模型探索并验证MFAP5影响卵巢癌细胞SKOV3恶性行为及耐药的相关通路。 结果: 在线数据分析显示,卵巢癌组织中MFAP5的表达明显高于正常卵巢组织(P<0.001)。免疫组化显示,MFAP5的表达主要集中于卵巢癌间质,且肿瘤分期越晚、肿瘤分级越高,MFAP5的表达越高。生存分析显示,MFAP5的高表达与患者不良预后相关,且只在较晚肿瘤分期、较高级别卵巢癌中意义明显。ssGSEA分析证明,MFAP5表达与卵巢癌上皮间充质转化、转移、侵袭相关基因集评分成正相关,GSE9891数据集中r值分别为0.54、0.40、0.67,TCGA594数据集r值分别为0.41、0.29、0.56(均P<0.001)。体外实验表明,敲降CAFs中MFAP5的表达不但可以部分降低其对卵巢癌上皮细胞SKOV3迁移、侵袭等恶性行为支持作用[对照组、si-NC组、si-MFAP5组细胞迁移数分别为:(73.44±7.80)个、(199.74±18.26)个、(91.21±6.70)个,细胞侵袭数分别为:(61.62±8.76)个、(174.81±15.23)个、(67.17±9.83)个],而且增加卵巢癌上皮细胞SKOV3对化疗、维持治疗的敏感性。MFAP5能够使卵巢癌细胞SKOV3中AKT信号通路活化,抑制AKT通路能够阻断MFAP5对卵巢癌细胞恶性行为及耐药的支持作用。 结论: MFAP5在卵巢癌中呈高表达状态,尤其在卵巢癌的间质组织中表达水平最高;MFAP5的高表达往往预示着卵巢癌患者的预后较差。通过敲降CAFs中MFAP5的表达,能够抑制其对卵巢癌上皮细胞恶性生物学行为及耐药性的支持作用,这一现象的潜在机制可能与阻断卵巢癌细胞中AKT信号通路有关。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li XT, Jia LL, Sun PC, et al. [The expression of MFAP5 in ovarian cancer and its effect on cancer cell proliferation, metastasis and drug resistance]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 41443738. doi:10.3760/cma.j.cn112152-20250501-00196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。